AusDiagnostics announces Scott Gilroy as new CEO

AusDiagnostics is delighted to announce the appointment of Scott Gilroy as its new CEO, effective Monday, August 24, 2020.

Mr Gilroy has been a key member of the AusDiagnostics executive and leadership team as Chief Operations Officer since August 2019 and will take on the leadership of the company from Founder and Managing Director, Professor Keith Stanley, who has led the company for the past 14 years.

Announcing Mr Gilroy’s appointment, Professor Stanley said: “Scott has not been with us long, but has already made a quantum leap in company performance, dealing with all the operational challenges caused by the COVID-19 pandemic and rapid expansion of the company.

“He is introducing new tools for management that will enable the company to continue to grow through the next phase of its development.”

Reflecting on his appointment, Mr Gilroy said: “I have always maintained a deep love for science and the way it changes our lives for the better. To have the opportunity to lead a dedicated and inspiring group of people at the heart of responding to the COVID-19 pandemic is truly humbling.

“We have some of the finest talent in the diagnostics field, a great culture and collaborative spirit, and dynamic capabilities in the market, that has enabled our strong and rapid growth. As a company, we have diversified and transitioned into a competitive global organisation. My mission is to build on our success and momentum to deliver even greater innovations and develop further expansion opportunities."

Innovation is a hallmark of AusDiagnostics’ work. Most recently, the organisation was one of the first to develop a molecular diagnostic test to detect the new coronavirus, COVID-19. Mr Gilroy said to be part of such progress was a privilege.

Professor Stanley will continue to deal with investors, governments and other companies through his position as Managing Director.

About AusDiagnostics:

AusDiagnostics Pty Ltd is a leading international company that designs, manufactures and markets a comprehensive suite of molecular diagnostic assays and reagents. Founded in August 2006, AusDiagnostics also supports robotic instruments for in vitro diagnostics and testing in the medical, veterinary, food, and water and environment industries. In the past five years, the company has expanded its reach to global customers through offices in New Zealand, the United Kingdom and the United States. In 2018, AusDiagnostics opened a manufacturing facility in the United Kingdom to support the supply of products to its growing network of distribution partners in more than 25 countries. AusDiagnostics continues to develop new technology, and conduct scientific research into innovative diagnostic methodologies to add value for customers across the globe.

For further details, contact: